Register Login

Terns Pharmaceuticals Inc (TERN)

(85% Positive) Terns Pharmaceuticals, Inc. (TERN) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 9:08 p.m.

    📋 Terns Pharmaceuticals, Inc. (TERN) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 16:05:23

    Event Type: Clinical Trial Update

    Event Details:

    Terns Pharmaceuticals Inc (TERN) Announces Clinical Trial Update Terns Pharmaceuticals Inc (TERN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, momentum
    • Diseases/Conditions: December, our CARDINAL tria
    • Clinical Stage: pivotal trial, Phase 1
    • Collaboration: U.S. FDA
    • Updated Timeline: 2025 Year-end

    🔬 Clinical Development Pipeline (Terns Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    PET/CT scan RADIATION Phase EARLY_PHASE1 Solid Tumor ClinicalTrials.gov
    89Zr-DFO-N-Suc-C9scFv BIOLOGICAL Phase EARLY_PHASE1 Solid Tumor ClinicalTrials.gov
    89Zr-DFO-N-Suc-F8scFv BIOLOGICAL Phase EARLY_PHASE1 Solid Tumor ClinicalTrials.gov
    Matching Placebo OTHER Phase PHASE2 Overweight or Obesity ClinicalTrials.gov
    TERN-601 DRUG Phase PHASE2 Overweight or Obesity ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Terns Pharmaceuticals Inc
    • CIK: 0001831363
    • Ticker Symbol: TERN
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories